Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21NO4 |
Molecular Weight | 315.3636 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5(O)CCC2=O)=CC=C3OC
InChI
InChIKey=BRUQQQPBMZOVGD-XFKAJCMBSA-N
InChI=1S/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1
Molecular Formula | C18H21NO4 |
Molecular Weight | 315.3636 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html
Curator's Comment: description was created based on several sources, including
http://reference.medscape.com/drug/oxycontin-xtampza-er-oxycodone-343321 | https://www.ncbi.nlm.nih.gov/pubmed/23880538 | https://www.drugs.com/oxycodone.html
Oxycodone is a semisynthetic opioid used for the management of acute and chronic pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Oxycodone is a highly selective full agonist of the μ-opioid receptor (MOR), with low affinity for the δ-opioid receptor (DOR) and κ-opioid receptor (KOR). After oxycodone binds to the MOR, a G protein-complex is released, which inhibits the release of neurotransmitters by the cell by reducing the amount of cAMP produced, closing calcium channels, and opening potassium channels. After a dose of conventional (instant-release) oral oxycodone, the onset of action is 10–30 minutes, and peak plasma levels of the drug are attained within roughly 30–60 minutes in contrast, after a dose of OxyContin (an oral controlled-release formulation), peak plasma levels of oxycodone occur in about three hours. The duration of instant-release oxycodone is 3 to 6 hours, although this can be variable depending on the individual. Oxycodone in the blood is distributed to skeletal muscle, liver, intestinal tract, lungs, spleen, and brain. Serious side effects of oxycodone include reduced sensitivity to pain (beyond the pain the drug is taken to reduce), euphoria, anxiolysis, feelings of relaxation, and respiratory depression. Common side effects of oxycodone include constipation (23%), nausea (23%), vomiting (12%), somnolence (23%), dizziness (13%), itching (13%), dry mouth (6%), and sweating (5%).
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538 |
500.0 nM [EC50] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538 |
16000.0 nM [EC50] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538 |
4000.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | PERCODAN-DEMI Approved UseOxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date-6.224256E11 |
|||
Primary | PERCODAN-DEMI Approved UseOxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date-6.224256E11 |
|||
Primary | PERCODAN-DEMI Approved UseOxyContin Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. OxyContin is NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for HealthCare Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. OxyContin is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. OxyContin is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) Launch Date-6.224256E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
19 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
22.2 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
17.7 ng/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
39.3 ng/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
15.7 ng/mL |
5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
12.9 ng/mL |
3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
105 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
128.2 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
133 ng × h/mL |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
268.2 ng × h/mL |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
113.3 ng × h/mL |
5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
99 ng × h/mL |
3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.9 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
3.55 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3.3 h |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
3.85 h |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
55% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FASTED |
|
55% |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55% |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: FED |
|
55% |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55% |
5 mg 4 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
55% |
3.33 mg 6 times / day steady-state, oral dose: 3.33 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
OXYCODONE unknown | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Co-administed with:: acetaminophen(1950 mg; single) Sources: cocaine(1/4 g; single) |
healthy, 30 years n = 1 Health Status: healthy Age Group: 30 years Sex: M Population Size: 1 Sources: |
Other AEs: Pulmonary edema... |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 1.7%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Dizziness (grade 1-2, 1.7%) Abdominal pain (grade 1-2, 0.8%) |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Headache, Vomiting... AEs leading to discontinuation/dose reduction: Headache (grade 1-2, 0.8%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Vomiting (grade 1-2, 0.8%) Nausea (grade 1-2, 0.8%) Somnolence (grade 1-2, 0.8%) |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (grade 1-2, 6.3%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Dizziness (grade 1-2, 4.8%) Confusion (grade 1-2, 3.2%) |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Disc. AE: Vomiting, Flu syndrome... AEs leading to discontinuation/dose reduction: Vomiting (grade 1-2, 0.8%) Sources: Page: /nda/98/20932_medr_P2.pdf - p.21Flu syndrome (grade 1-2, 0.8%) Confusion (grade 1-2, 0.8%) Fatigue (grade 1-2, 0.8%) |
6 mg 2 times / day single, oral (mean) Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: |
healthy, mean age 33 years n = 35 Health Status: healthy Age Group: mean age 33 years Sex: M+F Population Size: 35 Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (11.4%) Sources: |
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
healthy, mean age 36 years n = 40 Health Status: healthy Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.5%) Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pulmonary edema | 30 mg 1 times / day single, oral Studied dose Dose: 30 mg, 1 times / day Route: oral Route: single Dose: 30 mg, 1 times / day Co-administed with:: acetaminophen(1950 mg; single) Sources: cocaine(1/4 g; single) |
healthy, 30 years n = 1 Health Status: healthy Age Group: 30 years Sex: M Population Size: 1 Sources: |
|
Abdominal pain | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Dizziness | grade 1-2, 1.7% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Nausea | grade 1-2, 1.7% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 120 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 120 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Headache | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Nausea | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Somnolence | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Vomiting | grade 1-2, 0.8% Disc. AE |
20 mg 2 times / day multiple, oral (mean) Recommended Dose: 20 mg, 2 times / day Route: oral Route: multiple Dose: 20 mg, 2 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 125 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 125 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Confusion | grade 1-2, 3.2% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Dizziness | grade 1-2, 4.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Nausea | grade 1-2, 6.3% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 63 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 63 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Confusion | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Fatigue | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Flu syndrome | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Vomiting | grade 1-2, 0.8% Disc. AE |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
unhealthy, adult n = 126 Health Status: unhealthy Condition: chronic pain Age Group: adult Sex: M+F Population Size: 126 Sources: Page: /nda/98/20932_medr_P2.pdf - p.21 |
Vomiting | 11.4% Disc. AE |
6 mg 2 times / day single, oral (mean) Studied dose Dose: 6 mg, 2 times / day Route: oral Route: single Dose: 6 mg, 2 times / day Sources: |
healthy, mean age 33 years n = 35 Health Status: healthy Age Group: mean age 33 years Sex: M+F Population Size: 35 Sources: |
Vomiting | 2.5% Disc. AE |
15 mg 1 times / day single, oral Studied dose Dose: 15 mg, 1 times / day Route: oral Route: single Dose: 15 mg, 1 times / day Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
healthy, mean age 36 years n = 40 Health Status: healthy Age Group: mean age 36 years Sex: M+F Population Size: 40 Sources: Page: nda/2011/202080Orig1s000MedR.pdf - p.22 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major | ||||
minor | ||||
yes | ||||
yes | ||||
yes | yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). Page: 7.0 |
|||
yes | yes (co-administration study) Comment: When both oxidative pathways of the metabolism of oxycodone were inhibited with paroxetine and itraconazole (CYP3A4 AND CYP2D6 inhibitors), the mean AUC(0,∞) of oxycodone increased by 2.9-fold (P < 0.001), and its Cmax by 1.8-fold (P < 0.001). |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Advancement of opioid analgesia with controlled-release oxycodone. | 2001 |
|
Opioid formulations: tailoring to the needs in chronic pain. | 2001 |
|
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. | 2001 |
|
Strategies for the treatment of cancer pain in the new millennium. | 2001 |
|
Single-blind randomized clinical trial of laparoscopic versus open appendicectomy in children. | 2001 Apr |
|
The preemptive analgesic effect of intraarticular bupivacaine and morphine after ambulatory arthroscopic knee surgery. | 2001 Apr |
|
How one town got hooked. | 2001 Apr 9 |
|
Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. | 2001 Aug |
|
Time-release analgesic drug causes fatal overdoses in United States. | 2001 Aug |
|
"No, Duke. No divorce". | 2001 Aug 20 |
|
A curse and a cure. Is the crackdown on an abused drug causing needless suffering? | 2001 Aug 6 |
|
Opioid analgesic prescribing and use - an audit of analgesic prescribing by general practitioners and The Multidisciplinary Pain Centre at Royal Brisbane Hospital. | 2001 Dec |
|
OxyContin abuse. | 2001 Feb |
|
On the frontlines of old battles. | 2001 Jul |
|
Identification of ozone-oxidation products of oxycodone by electrospray ion trap mass spectrometry. | 2001 Jul |
|
Stability indicating HPLC method for the estimation of oxycodone and lidocaine in rectal gel. | 2001 Jul 31 |
|
Preoperative diclofenac is a useful adjunct to spinal anesthesia for day-case varicose vein repair. | 2001 Jul-Aug |
|
Relative variability in bioavailability of oral controlled-release formulations of oxycodone and morphine. | 2001 Jul-Aug |
|
I.v. ketoprofen for analgesia after tonsillectomy: comparison of pre- and post-operative administration. | 2001 Mar |
|
Painkiller crackdown. | 2001 May 14 |
|
[Treatment of pain in cancer with systemically administered opioids]. | 2001 May 19 |
|
The use of oxycodone in cancer-related pain: a literature review. | 2001 Nov |
|
Clinical case study. | 2001 Nov-Dec |
|
States respond to growing abuse of painkiller. | 2001 Oct-Nov |
|
Managing postoperative pain. | 2001 Sep |
|
Interscalene brachial plexus block with continuous intraarticular infusion of ropivacaine. | 2001 Sep |
|
Oxycodone and oxycontin. | 2001 Sep 17 |
|
Oxy's offspring. | 2002 Apr 22 |
|
More blame and praise for a pain drug. | 2002 Apr 29 |
|
Severe chronic renal failure in association with oxycodone addiction: a new form of fibrillary glomerulopathy. | 2002 Aug |
|
Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children. | 2002 Feb |
|
Comparison of the pharmacokinetics of oxycodone administered in three Percocet formulations. | 2002 Feb |
|
Perioperative management in children with sickle cell disease undergoing laparoscopic surgery. | 2002 Jan-Mar |
|
Safety and efficacy of controlled-release oxycodone: a systematic literature review. | 2002 Jul |
|
There is no accounting for accountability. | 2002 Mar |
|
OxyContin Use and Abuse. | 2002 Mar-Apr |
|
Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. | 2002 Nov |
|
Simultaneous quantitation of opioids in blood by GC-EI-MS analysis following deproteination, detautomerization of keto analytes, solid-phase extraction, and trimethylsilyl derivatization. | 2002 Oct |
|
Detection of cocaine analytes and opiates in nails from postmortem cases. | 2002 Oct |
|
Pharmacogenomics as molecular autopsy for postmortem forensic toxicology: genotyping cytochrome P450 2D6 for oxycodone cases. | 2002 Oct |
|
Massive OxyContin ingestion refractory to naloxone therapy. | 2002 Oct |
|
Interscalene brachial plexus block is superior to subacromial bursa block after arthroscopic shoulder surgery. | 2002 Sep |
|
Review: tricyclic antidepressants, capsaicin, gabapentin, and oxycodone are effective for postherpetic neuralgia. | 2002 Sep-Oct |
|
Oxycontin--misuse and abuse. | 2002 Summer |
Sample Use Guides
For opioid naïve patients, initiate treatment with 5 mg to 15 mg every 4 to 6 hours as needed for pain.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23880538
Human embryonic kidney (HEK)-293 were used for activity evaluation. Receptor G protein-mediated responses were determined by measuring changes in cAMP using the cAMP–homogenous timeresolved fluorescence kit (Cisbio, Codolet, France). MOR, KOR, DOR all couple to Gai so G protein coupling was measured as inhibition of forskolin-stimulated cAMP accumulation in the presence of 1.5 mkM NKH-477 (water-soluble forskolin, Tocris catalog #1603) and 500 mkM 3-isobutyl-1-methylxanthine (IBMX). cAMP accumulation assays were run in parallel with b-arrestin-2 recruitment, using the same cells, drug dilutions, and assay buffers [1% dimethylsulfoxide (DMSO), F12 Ham’s buffer] to ensure accurate assay-to-assay comparisons of data. Plates were read using a time-resolved fluorescence ratio (665 nm/620 nm) on a PheraStar plate reader
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 16:01:39 UTC 2022
by
admin
on
Fri Dec 16 16:01:39 UTC 2022
|
Record UNII |
CD35PMG570
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02AA56
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-ATC |
N02AA05
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-VATC |
QN02AA05
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
LIVERTOX |
NBK547955
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
DEA NO. |
9143
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
NDF-RT |
N0000175690
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-ATC |
N02AJ18
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-VATC |
QN02AA55
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-ATC |
N02AJ19
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
NDF-RT |
N0000175684
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-ATC |
N02AJ17
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
||
|
WHO-ATC |
N02AA55
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID5023407
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
7093
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
5284603
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
CHEMBL656
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
CD35PMG570
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
200-960-2
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
CD35PMG570
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
3142
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
1485191
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
D010098
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
76-42-6
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
M8328
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | Merck Index | ||
|
OXYCODONE
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
DB00497
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
19043
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
Oxycodone
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
C29309
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
7852
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
SUB09562MIG
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
7804
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | RxNorm | ||
|
2029
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY | |||
|
1701
Created by
admin on Fri Dec 16 16:01:39 UTC 2022 , Edited by admin on Fri Dec 16 16:01:39 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DERIVATIVE -> PARENT |
|
||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
LABELED -> NON-LABELED |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST | |||
|
SALT/SOLVATE -> PARENT |
APPROXIMATE PURE ANHYDROUS DRUG CONTENT (IN PERCENT)
|
||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
MAJOR
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
MINOR
PLASMA; URINE
|
||
|
METABOLITE ACTIVE -> PARENT |
Highly variable 40 fold higher potency than Oxycodone
MINOR
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
||||
MAXIMUM TOLERATED DOSE | TOXICITY |
|
||||
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||